The web Browser you are currently using is unsupported, and some features of this site may not work as intended. Please update to a modern browser such as Chrome, Firefox or Edge to experience all features Michigan.gov has to offer.
RSV Information for Healthcare
RSV: Resources for Health Professionals
RSV usually causes mild symptoms, but it can cause severe illness. This is more likely in infants, some young children, people with compromised immune systems and adults who are older or have certain risk factors.
Healthcare providers should consider RSV in the differential diagnosis of patients with respiratory illness, particularly during the RSV season.
To protect infants and some young children, CDC recommends the maternal RSV vaccine (Pfizer’s Abrysvo) for pregnant women during weeks 32–36 of pregnancy, or a long-acting infant RSV antibody (nirsevimab or clesrovimab) for babies given after birth. Nirsevimab is recommended for some young children ages 8–19 months.
CDC also recommends a single dose of RSV vaccine to protect all adults ages 75 and older and adults ages 50–74 who are at increased risk of severe RSV.
-
Visit the Vaccine Information Statements webpage for more information or see the Respiratory Syncytial Virus (RSV) Vaccine VIS and the RSV Preventive Antibody (nirsevimab) Immunization Information Statement (IIS) on the CDC website.
-
Reporting
RSV-associated pediatric deaths in children younger than 18 years are required to be reported in Michigan.
How to report an RSV-associated pediatric death:
- Report to your local health department (LHD). Find your county’s contact information in the LHD contact information dropdown menu.
- Report directly to MDHHS by contacting the MDHHS Respiratory Virus unit at MDHHS-RespVirus@michigan.gov.
For a complete list of reportable conditions in Michigan, visit Michigan’s List of Reportable Diseases by Condition or Michigan’s List of Reportable Diseases by Pathogen.
Surveillance
For the latest respiratory disease surveillance data in Michigan, visit the Michigan Respiratory Disease Reports webpage or see the most recent Michigan Flu Focus Report. These resources provide regularly updated information on influenza, COVID-19 and RSV activity across Michigan, including emergency department visits, hospitalizations, outbreaks and immunization trends.
CDC has several systems that focus on monitoring and describing seasonal trends, clinical risk factors, rates of illness and hospitalization and demographics of patients seeking care for illness associated with RSV. Visit the CDC’s Surveillance of RSV webpage for more information.
-
Visit the CDC’s Clinical Overview of RSV webpage for an overview of RSV for healthcare providers, including clinical features, populations at increased risk for severe disease, RSV immunization recommendations and links to CDC guidance for infants, pregnant patients and adults.
-
Use the resources below to determine eligibility, timing, dosage and administration of RSV vaccines and preventive antibodies. Always refer to the most current recommendations before administering an RSV product.
Michigan Immunization Recommendations
Immunization can reduce the risk of RSV-related hospitalization and other serious complications. See Michigan’s current RSV immunization recommendation document for more information.
RSV Preventive Antibody Guidance
Use the Clesrovimab Guide for RSV for more information on the use, eligibility, dosing, administration and other clinical considerations for clesrovimab.
Use the Nirsevimab Guide for RSV for more information on the use, eligibility, dosing, administration and other clinical considerations for nirsevimab.
MMWR Recommendations
- Infants and Young Children: Use of Nirsevimab for the Prevention of Respiratory Syncytial Virus Disease Among Infants and Young Children – CDC recommendations for the use of nirsevimab to prevent RSV disease in infants and eligible young children.
- Older Adults: Use of Respiratory Syncytial Virus Vaccines in Older Adults – CDC recommendations for RSV vaccination of older adults, including age and risk-based recommendations.
- Pregnancy: Use of the Pfizer Respiratory Syncytial Virus Vaccine During Pregnancy for the Prevention of Respiratory Syncytial Virus-Associated Lower Respiratory Tract Disease in Infants – CDC recommendations for use of RSV vaccine during pregnancy to prevent RSV-associated lower respiratory tract disease in infants.
-
Provide patients and families with clear, accessible information about RSV and prevention options.
- RSV information for the public: Direct patients to RSV Information for the Public webpage for more information on RSV, symptoms, prevention and when to seek medical care.
- RSV vaccination: Provide the RSV Vaccine Information Statement (VIS) before administering an RSV vaccine.
- RSV preventive antibodies: For infants and children receiving an RSV preventive antibody, provide the appropriate RSV Preventive Antibody Immunization Information Statement (IIS).